美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Medicus Pharma Ltd.

1.00

-0.0300-2.91%

成交量：3.39萬

成交額：3.49萬

市值：2,511.41萬

市盈率：-0.47

高：1.05

開：1.05

低：0.9900

收：1.03

52周最高：8.94

52周最低：0.9900

股本：2,511.41萬

流通股本：1,857.02萬

量比：1.13

換手率：0.18%

股息：- -

股息率：- -

每股收益(TTM):-2.1105

每股收益(LYR):-1.1597

淨資產收益率：-2660.81%

總資產收益率：-170.69%

市淨率：-27.59

市盈率(LYR):-0.86

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

Medicus Pharma獲FDA批准Teverelix®針對高心血管風險晚期前列腺癌患者的IIb期研究可繼續進行

BUZZ-削減teverelix特許權使用費後，Medicus Pharma股價上漲

Medicus Pharma Ltd.修訂協議未改變授權範圍、核心知識產權及雙方開發職責

Medicus Pharma Ltd. 宣佈修訂Lifearc許可協議，優化Teverelix®長期經濟與開發前景

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/MDCX"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":1,"timestamp":1770821254961,"preClose":1.03,"halted":0,"volume":33888,"delay":0,"changeRate":-0.029126213592233035,"floatShares":18570200,"shares":25114144,"eps":-2.1105,"marketStatus":"交易中","change":-0.03,"latestTime":"02-11 09:50:22 EST","open":1.05,"high":1.05,"low":0.99,"amount":34927.2737952,"amplitude":0.058252,"askPrice":1.03,"askSize":417,"bidPrice":1,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-2.1105,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1770843600000},"marketStatusCode":2,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":1.03,"preHourTrading":{"tag":"盘前","latestPrice":1.03,"preClose":1.03,"latestTime":"09:29 EST","volume":3636,"amount":3665.9013732000003,"timestamp":1770820199153,"change":0,"changeRate":0,"amplitude":0.035825},"postHourTrading":{"tag":"盘后","latestPrice":1.0391,"preClose":1.03,"latestTime":"19:59 EST","volume":10195,"amount":10346.0809,"timestamp":1770771569114,"change":0.0091,"changeRate":0.008835,"amplitude":0.037961},"volumeRatio":1.129018},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":18570200,"roa":"-170.69%","roe":"-2660.81%","lyrEps":-1.159715,"volumeRatio":1.129018,"shares":25114144,"dividePrice":0,"high":1.05,"amplitude":0.058252,"preClose":1.03,"low":0.99,"week52Low":0.99,"pbRate":"-27.59","week52High":8.94,"institutionHeld":0,"latestPrice":1,"committee":-0.976303,"eps":-2.1105,"divideRate":0,"volume":33888,"delay":0,"ttmEps":-2.1105,"open":1.05,"prevYearClose":1.53,"prevWeekClose":1.11,"prevMonthClose":1.19,"prevQuarterClose":1.53,"fiveDayClose":1.15,"twentyDayClose":1.45,"sixtyDayClose":2.26},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[{"date":"2025-11-14","symbol":"MDCX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763154000000,"name":null,"time":"盤後","dateTimestamp":1763096400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1744606800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MDCX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MDCX","date":"2026-02-09","current":-0.488036,"percent":0.991304,"low":-3.23298,"twenty":-2.861786,"median":-2.048051,"eighty":-1.018593,"high":-0.765701,"avg":-1.917502,"sd":0.855443,"marketCap":28360481},"quantilePoints":[{"date":"2025-08-29","current":-2.084531,"twenty":-2.272139,"median":-2.126221,"eighty":-2.109545,"marketCap":35632532},{"date":"2025-09-05","current":-1.907346,"twenty":-2.205434,"median":-2.115799,"eighty":-2.053263,"marketCap":32603766},{"date":"2025-09-12","current":-2.345097,"twenty":-2.211687,"median":-2.12101,"eighty":-2.053263,"marketCap":40086598},{"date":"2025-09-19","current":-2.532705,"twenty":-2.511859,"median":-2.178335,"eighty":-2.080362,"marketCap":43293526},{"date":"2025-09-26","current":-2.817408,"twenty":-2.759151,"median":-2.287772,"eighty":-2.103292,"marketCap":48160186},{"date":"2025-10-03","current":-3.005474,"twenty":-2.869667,"median":-2.511859,"eighty":-2.115799,"marketCap":51374941},{"date":"2025-10-10","current":-3.005474,"twenty":-2.994879,"median":-2.558762,"eighty":-2.122052,"marketCap":51374941},{"date":"2025-10-17","current":-2.885734,"twenty":-2.976858,"median":-2.720313,"eighty":-2.151236,"marketCap":49328130},{"date":"2025-10-24","current":-2.909682,"twenty":-2.974342,"median":-2.774974,"eighty":-2.174166,"marketCap":49737492},{"date":"2025-10-31","current":-2.957578,"twenty":-2.974342,"median":-2.817408,"eighty":-2.178335,"marketCap":50556216},{"date":"2025-11-07","current":-2.897708,"twenty":-2.962368,"median":-2.809662,"eighty":-2.228364,"marketCap":49532811},{"date":"2025-11-14","current":-2.706124,"twenty":-2.950394,"median":-2.817408,"eighty":-2.292984,"marketCap":46257915},{"date":"2025-11-21","current":-1.28141,"twenty":-2.950394,"median":-2.789942,"eighty":-2.178335,"marketCap":44939453},{"date":"2025-11-28","current":-1.355609,"twenty":-2.936025,"median":-2.763,"eighty":-2.119968,"marketCap":48464116},{"date":"2025-12-05","current":-1.183077,"twenty":-2.916866,"median":-2.742046,"eighty":-2.04284,"marketCap":42295956},{"date":"2025-12-12","current":-1.201563,"twenty":-2.904892,"median":-2.700137,"eighty":-1.376181,"marketCap":42956830},{"date":"2025-12-19","current":-1.022869,"twenty":-2.897708,"median":-2.63428,"eighty":-1.31987,"marketCap":36568379},{"date":"2025-12-26","current":-0.955088,"twenty":-2.897553,"median":-2.584818,"eighty":-1.266827,"marketCap":34145173},{"date":"2026-01-02","current":-1.074791,"twenty":-2.896932,"median":-2.511859,"eighty":-1.220048,"marketCap":38424640},{"date":"2026-01-09","current":-1.095865,"twenty":-2.885734,"median":-2.329463,"eighty":-1.179996,"marketCap":39178064},{"date":"2026-01-16","current":-0.976444,"twenty":-2.885734,"median":-2.178335,"eighty":-1.123965,"marketCap":34908660},{"date":"2026-01-23","current":-0.94132,"twenty":-2.866576,"median":-2.167912,"eighty":-1.101485,"marketCap":33652952},{"date":"2026-01-30","current":-0.878097,"twenty":-2.861786,"median":-2.115799,"eighty":-1.061072,"marketCap":31392680},{"date":"2026-02-06","current":-0.765701,"twenty":-2.861786,"median":-2.074108,"eighty":-1.022014,"marketCap":27374416},{"date":"2026-02-09","current":-0.793282,"twenty":-2.861786,"median":-2.048051,"eighty":-1.018593,"marketCap":28360481}],"updateTime":1770795552427},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1179126983","title":"Medicus Pharma獲FDA批准Teverelix®針對高心血管風險晚期前列腺癌患者的IIb期研究可繼續進行","url":"https://stock-news.laohu8.com/highlight/detail?id=1179126983","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179126983?lang=zh_tw&edition=fundamental","pubTime":"2026-02-10 20:30","pubTimestamp":1770726624,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 宣布，其用于治疗伴有高心血管风险的晚期前列腺癌患者的Teverelix® IIb期临床试验，已获得美国食品药品监督管理局（FDA）的“研究可继续进行”许可。这一监管里程碑意味着公司可以按计划推进该临床阶段的研究工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"2605994374","title":"BUZZ-削減teverelix特許權使用費後，Medicus Pharma股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2605994374","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605994374?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 21:04","pubTimestamp":1769087043,"startTime":"0","endTime":"0","summary":"BUZZ-削减teverelix特许权使用费后，Medicus Pharma股价上涨1月22日 - ** 药物开发商Medicus Pharma MDCX.O股价盘前上涨12%至1.49美元 ** 该公司表示，在修订与英国研究机构LifeArc的协议后，已将前列腺癌试验药物teverelix的专利使用费从~4%降至2%。** 公司的 teverelix 正在接受晚期前列腺癌和复发性急性尿潴留的测试。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nL4S3YN128:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"1184034229","title":"Medicus Pharma Ltd.修訂協議未改變授權範圍、核心知識產權及雙方開發職責","url":"https://stock-news.laohu8.com/highlight/detail?id=1184034229","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184034229?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 20:33","pubTimestamp":1769085202,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 近日宣布，其对现有协议的修订并未对原授权协议的范围、基础知识产权归属或合作双方各自的开发责任产生任何实质性改变。此次修订旨在优化合作条款，确保项目推进效率，同时维持原有知识产权框架与开发义务的稳定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"1127677442","title":"Medicus Pharma Ltd. 宣佈修訂Lifearc許可協議，優化Teverelix®長期經濟與開發前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1127677442","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127677442?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 20:31","pubTimestamp":1769085098,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 已宣布对其与Lifearc达成的许可协议进行修订。此次修订旨在显著提升其核心产品Teverelix®的长期经济价值和开发潜力。协议的调整预计将为该药物的未来商业化道路带来更有利的条件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/MDCX\",params:#limit:6,delay:false,,,undefined,":[]}}